Cytoreductive Surgery and HIPEC in Recurrent Epithelial Ovarian Cancer: A Prospective Randomized Phase III Study

Background The current treatment of ovarian cancer consists of cytoreductive surgery (CRS) and systemic chemotherapy. The aim of this study was to examine if hyperthermic intraperitoneal chemotherapy (HIPEC) is an alternative modality to treat this category of patients along with a second attempt of...

Full description

Saved in:
Bibliographic Details
Published in:Annals of surgical oncology 2015-05, Vol.22 (5), p.1570-1575
Main Authors: Spiliotis, J., Halkia, E., Lianos, E., Kalantzi, N., Grivas, A., Efstathiou, E., Giassas, S.
Format: Article
Language:English
Subjects:
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Carcinoma, Ovarian Epithelial
Combined Modality Therapy
Cytoreduction Surgical Procedures - mortality
Female
Follow-Up Studies
Gynecologic Oncology
Humans
Hyperthermia, Induced - mortality
Injections, Intraperitoneal
Lymphatic Metastasis
Medicine
Medicine & Public Health
Middle Aged
Neoplasm Invasiveness
Neoplasm Recurrence, Local - mortality
Neoplasm Recurrence, Local - pathology
Neoplasm Recurrence, Local - therapy
Neoplasm Staging
Neoplasms, Glandular and Epithelial - mortality
Neoplasms, Glandular and Epithelial - pathology
Neoplasms, Glandular and Epithelial - therapy
Oncology
Ovarian Neoplasms - mortality
Ovarian Neoplasms - pathology
Ovarian Neoplasms - therapy
Peritoneal Neoplasms - mortality
Peritoneal Neoplasms - secondary
Peritoneal Neoplasms - therapy
Prognosis
Prospective Studies
Surgery
Surgical Oncology
Survival Rate
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The current treatment of ovarian cancer consists of cytoreductive surgery (CRS) and systemic chemotherapy. The aim of this study was to examine if hyperthermic intraperitoneal chemotherapy (HIPEC) is an alternative modality to treat this category of patients along with a second attempt of surgical resection and second- or third-line systemic chemotherapy afterward. Methods In an 8-year period (2006–2013), 120 women with advanced ovarian cancer (International Federation of Gynecology and Obstetrics [FIGO] III c and IV) who experienced disease recurrence after initial treatment with conservative or debulking surgery and systemic chemotherapy were randomized into two groups. Group A comprised 60 patients treated with CRS followed by HIPEC and then systemic chemotherapy. Group B comprised 60 patients treated with CRS only and systemic chemotherapy. Results The mean survival for group A was 26.7 versus 13.4 months in group B ( p  
ISSN:1068-9265
1534-4681
DOI:10.1245/s10434-014-4157-9